Tags

Type your tag names separated by a space and hit enter

Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions.
J Eur Acad Dermatol Venereol. 2013 Feb; 27(2):e224-30.JE

Abstract

BACKGROUND

Epidermolysis bullosa acquisita (EBA) is a chronic autoimmune subepidermal bullous disease characterized by circulating autoantibodies against type VII collagen. Detecting these autoantibodies is crucial for the diagnosis of this disease, and is also useful for measuring disease activity. Enzyme-linked immunosorbent assay (ELISA), a quantitative method to measure anti-type VII collagen antibody levels, is currently available to diagnose EBA.

OBJECTIVE

The aim of this study was to investigate the relationship of ELISA with overall clinical severity.

METHODS

Sera from patients with EBA (n = 30), bullous pemphigoid (n = 20), anti-laminin γ1 pemphigoid (n = 9) and healthy donors (n = 24) were tested using ELISA, using the recombinant non-collagenous 1 (NC1) and 2 (NC2) domains of type VII collagen. Relationships between clinical characteristics, indirect immunofluoroscence (IIF) titres and ELISA values were investigated.

RESULTS

The sensitivity and specificity of the EBA ELISA were 96.7% and 98.1%, respectively. There was no significant difference between ELISA results for classic and inflammatory types. The severity of skin involvement was positively correlated with both ELISA value (r = 0.87, P < 0.01) and IIF titre (r = 0.59, P < 0.01). Time sequence analysis in four patients with EBA showed that ELISA values reflect disease activity better than IIF titres.

CONCLUSIONS

Type VII collagen ELISA using the NC1 and NC2 domains is useful for diagnosing EBA and monitoring disease severity.

Authors+Show Affiliations

Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22731917

Citation

Kim, J H., et al. "Serum Levels of Anti-type VII Collagen Antibodies Detected By Enzyme-linked Immunosorbent Assay in Patients With Epidermolysis Bullosa Acquisita Are Correlated With the Severity of Skin Lesions." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 27, no. 2, 2013, pp. e224-30.
Kim JH, Kim YH, Kim S, et al. Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. J Eur Acad Dermatol Venereol. 2013;27(2):e224-30.
Kim, J. H., Kim, Y. H., Kim, S., Noh, E. B., Kim, S. E., Vorobyev, A., Schmidt, E., Zillikens, D., & Kim, S. C. (2013). Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. Journal of the European Academy of Dermatology and Venereology : JEADV, 27(2), e224-30. https://doi.org/10.1111/j.1468-3083.2012.04617.x
Kim JH, et al. Serum Levels of Anti-type VII Collagen Antibodies Detected By Enzyme-linked Immunosorbent Assay in Patients With Epidermolysis Bullosa Acquisita Are Correlated With the Severity of Skin Lesions. J Eur Acad Dermatol Venereol. 2013;27(2):e224-30. PubMed PMID: 22731917.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. AU - Kim,J H, AU - Kim,Y H, AU - Kim,S, AU - Noh,E B, AU - Kim,S-E, AU - Vorobyev,A, AU - Schmidt,E, AU - Zillikens,D, AU - Kim,S-C, Y1 - 2012/06/25/ PY - 2012/6/27/entrez PY - 2012/6/27/pubmed PY - 2013/7/3/medline SP - e224 EP - 30 JF - Journal of the European Academy of Dermatology and Venereology : JEADV JO - J Eur Acad Dermatol Venereol VL - 27 IS - 2 N2 - BACKGROUND: Epidermolysis bullosa acquisita (EBA) is a chronic autoimmune subepidermal bullous disease characterized by circulating autoantibodies against type VII collagen. Detecting these autoantibodies is crucial for the diagnosis of this disease, and is also useful for measuring disease activity. Enzyme-linked immunosorbent assay (ELISA), a quantitative method to measure anti-type VII collagen antibody levels, is currently available to diagnose EBA. OBJECTIVE: The aim of this study was to investigate the relationship of ELISA with overall clinical severity. METHODS: Sera from patients with EBA (n = 30), bullous pemphigoid (n = 20), anti-laminin γ1 pemphigoid (n = 9) and healthy donors (n = 24) were tested using ELISA, using the recombinant non-collagenous 1 (NC1) and 2 (NC2) domains of type VII collagen. Relationships between clinical characteristics, indirect immunofluoroscence (IIF) titres and ELISA values were investigated. RESULTS: The sensitivity and specificity of the EBA ELISA were 96.7% and 98.1%, respectively. There was no significant difference between ELISA results for classic and inflammatory types. The severity of skin involvement was positively correlated with both ELISA value (r = 0.87, P < 0.01) and IIF titre (r = 0.59, P < 0.01). Time sequence analysis in four patients with EBA showed that ELISA values reflect disease activity better than IIF titres. CONCLUSIONS: Type VII collagen ELISA using the NC1 and NC2 domains is useful for diagnosing EBA and monitoring disease severity. SN - 1468-3083 UR - https://www.unboundmedicine.com/medline/citation/22731917/Serum_levels_of_anti_type_VII_collagen_antibodies_detected_by_enzyme_linked_immunosorbent_assay_in_patients_with_epidermolysis_bullosa_acquisita_are_correlated_with_the_severity_of_skin_lesions_ L2 - https://doi.org/10.1111/j.1468-3083.2012.04617.x DB - PRIME DP - Unbound Medicine ER -